BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
BriaCell Therapeutics Corp.
Financials through Q3 FY2026, quarter ended Apr 30, 2026Last filing: 10-Q on Jun 9, 2026
$3.38−0.02 (-0.59%)
Close on Oct 19, 2026
- Market cap
- $24.51M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$8.47 (−71.48%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Apr 30, 2026
Valuation
- Market cap
- $24.51M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$30.68M
- EPS, diluted
- -$62.19
- Diluted shares
- 7M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$32.03M
Net income
-$30.68M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months